Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Goncalves, A; Rey, J; Buchele, T; Loibl, S.
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
ANN ONCOL. 2022; 33: S148-S149.
Doi: 10.1016/j.annonc.2022.03.074
[Poster]
Web of Science
FullText
FullText_MUG